声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。3月4日,德琪医药发布公告宣布,与优时比(UCB)达成授权协议。根据授权协议,德琪医药授予优时比进一步开发、生产及商业化ATG-201,并使用相关生产技术的全球独家授权。德琪医药将获得8000万美元的首付款及近期里程碑付款(包括6000万美元的首付款以及...
Source Link声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。3月4日,德琪医药发布公告宣布,与优时比(UCB)达成授权协议。根据授权协议,德琪医药授予优时比进一步开发、生产及商业化ATG-201,并使用相关生产技术的全球独家授权。德琪医药将获得8000万美元的首付款及近期里程碑付款(包括6000万美元的首付款以及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.